VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Edwards Lifesciences Corporation vs Eli Lilly and Company

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Edwards Lifesciences Corporation

EW · New York Stock Exchange

Market cap (USD)$46.8B
Gross margin (TTM)78.1%
Operating margin (TTM)26.7%
Net margin (TTM)17.6%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-31
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Edwards Lifesciences Corporation's moat claims, evidence, and risks.

View EW analysis

Eli Lilly and Company

LLY · New York Stock Exchange

Market cap (USD)$952.3B
Gross margin (TTM)83.8%
Operating margin (TTM)45.6%
Net margin (TTM)31.7%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-08
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.

View LLY analysis

Comparison highlights

  • Moat score: both at 82 / 100.
  • Segment focus: Edwards Lifesciences Corporation has 3 segments (75.5% in Transcatheter Aortic Valve Replacement (TAVR)); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: Edwards Lifesciences Corporation has 6 moat types across 3 domains; Eli Lilly and Company has 5 across 3.

Primary market context

Edwards Lifesciences Corporation

Transcatheter Aortic Valve Replacement (TAVR)

Market

Transcatheter aortic valve replacement (TAVR) devices

Geography

Global

Customer

Hospitals and structural heart centers

Role

Medical device manufacturer

Revenue share

75.5%

Eli Lilly and Company

Cardiometabolic Health

Market

Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)

Geography

Global (with U.S. as the largest market)

Customer

Patients via prescribers and payers (commercial/government)

Role

Branded drug developer/manufacturer

Revenue share

65.5%

Side-by-side metrics

Edwards Lifesciences Corporation
Eli Lilly and Company
Ticker / Exchange
EW - New York Stock Exchange
LLY - New York Stock Exchange
Market cap (USD)
$46.8B
$952.3B
Gross margin (TTM)
78.1%
83.8%
Operating margin (TTM)
26.7%
45.6%
Net margin (TTM)
17.6%
31.7%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Drug Manufacturers - General
HQ country
US
US
Primary segment
Transcatheter Aortic Valve Replacement (TAVR)
Cardiometabolic Health
Market structure
Oligopoly
Oligopoly
Market share
60%-73% (estimated)
55%-59% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
82 / 100
82 / 100
Moat domains
Demand, Legal, Supply
Legal, Supply, Demand
Last update
2025-12-31
2026-01-08

Moat coverage

Shared moat types

Regulated Standards PipeIP Choke Point

Edwards Lifesciences Corporation strengths

Brand TrustTraining Org Change CostsCompliance AdvantageSupply Chain Control

Eli Lilly and Company strengths

Capacity MoatReputation ReviewsCapex Knowhow Scale

Segment mix

Edwards Lifesciences Corporation segments

Full profile >

Transcatheter Aortic Valve Replacement (TAVR)

Oligopoly

75.5%

Transcatheter Mitral and Tricuspid Therapies (TMTT)

Competitive

6.5%

Surgical Structural Heart

Oligopoly

18%

Eli Lilly and Company segments

Full profile >

Cardiometabolic Health

Oligopoly

65.5%

Oncology

Competitive

19.4%

Immunology

Oligopoly

9.8%

Neuroscience

Competitive

3.3%

Other

Competitive

2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.